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Abstract: Alzheimer’s disease (AD) is a major health problem and a growing recognition 
exists that efforts to prevent it must be undertaken by both governmental and  
non-governmental organizations. In this context, the pineal product, melatonin, has a 
promising significance because of its chronobiotic/cytoprotective properties potentially 
useful for a number of aspects of AD. One of the features of advancing age is the gradual 
decrease in circulating melatonin levels. A limited number of therapeutic trials have 
indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment 
of AD and minimal cognitive impairment (which may evolve to AD). Both in vitro and  
in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD. 
For these effects to occur, doses of melatonin about two orders of magnitude higher than 
those required to affect sleep and circadian rhythmicity are needed. More recently, 
attention has been focused on the development of potent melatonin analogs with prolonged 
effects, which were employed in clinical trials in sleep-disturbed or depressed patients in 
doses considerably higher than those employed for melatonin. In view that the relative 
potencies of the analogs are higher than that of the natural compound, clinical trials 
employing melatonin in the range of 50–100 mg/day are urgently needed to assess its 
therapeutic validity in neurodegenerative disorders such as AD. 
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1. Introduction 
Neurodegenerative disorders are a group of chronic and progressive diseases characterized by 
selective and symmetric losses of neurons in cognitive, motor, or sensory systems. Alzheimer’s disease 
(AD) is the most clinically relevant representative of this type of disorders. Although the origin of the 
specific neurodegeneration in AD remains undefined, three major and frequently interrelated 
processes, namely free radical-mediated damage, mitochondrial dysfunction, and excitotoxicity, 
underlie the pathophysiological mechanisms leading to neuronal death [1]. 
AD has a very large impact on health. In a recent publication [2] the Alzheimer’s Disease 
International (ADI) organization states that 44 million people live with dementia today and that this 
figure will rise to 135 million people by 2050. The current economic cost of dementia is $604 billion 
annually. It must be noted that the new estimates are an increase of 17% on the figures published in 
2009, population aging being the main driver of the projected increase. The ADI report also predicts a 
shift in the distribution of the global burden of dementia by 2050, with 71% of all affected people 
living in low- or middle-income countries. It is estimated that 10% of dementia cases may be avoided 
by campaigns that target obesity, hypertension, diabetes, underactivity, and smoking, as well as by 
education and cognitive enhancement. Thus, a growing recognition exists that efforts to prevent AD at 
an early stage of development must be urgently undertaken. 
The regular intake of antioxidants by the elderly has been one of the strategies recommended for 
prevention of age-associated, free radical-mediated, neurodegenerative diseases, but the efficacy of 
this treatment is debated [3]. In this context, the use of melatonin as a cytoprotective agent becomes of 
great interest. Melatonin is a well-conserved methoxyindole found in most phyla and having 
remarkable cytoprotective actions in addition to chronobiotic properties. The source of circulating 
melatonin is the pineal gland, and a substantial amount of data support that plasma melatonin decrease 
is one of the features of advancing age [4]. We will briefly review some relevant aspects of 
melatonin’s biology as far as the neurodegenerative process is concerned. Then, the theory and mode 
of action of melatonin in AD will be discussed. Finally, the clinical studies supporting the therapeutic 
use of melatonin in AD will be critically assessed. 
2. Basic Biology of Melatonin Relevant to Neurodegeneration 
Circulating melatonin in mammals derives almost exclusively from the pineal gland [5]. In addition, 
melatonin is locally synthesized in many cells, tissues, and organs, including lymphocytes, bone 
marrow, the thymus, the gastrointestinal tract, skin, and the eyes (see [6,7]). The fact that the 
occurrence of melatonin is not restricted to vertebrates, but rather is almost ubiquitously present in 
numerous taxa including, e.g., bacteria, unicellular eukaryotes, and plants [6,8], underlines that this 
molecule has gained many additional functions in the course of evolution. 
Antioxidants 2014, 3 247 
 
 
Both in other animals and in humans, melatonin participates in diverse physiological functions 
signaling not only the length of the night but also facilitating, among other, free radical scavenging and 
the immune response, thus, showing relevant cytoprotective properties [6]. Indeed, cytoprotection may 
well explain melatonin’s presence in most living organisms. The systemic and intracellular functions 
of melatonin differ in the amounts of agonist needed. Generally melatonin effects on biologic rhythms 
are exerted at nanomolar concentrations and via receptor-mediated mechanisms. The cytoprotective 
effects of melatonin needs 100–1000 higher concentrations, compatible with the amounts reached 
intracellularly by melatonin in several tissues [7]. 
Circulating melatonin binds to albumin [9] and is metabolized mainly in the liver primarily through 
hydroxylation at the C6 position. This is catalyzed selectively by the hepatic microsomal cytochrome 
P450 1A2 (CYP1A2), with minor contributions from hepatic CYP2C19 and the largely extrahepatic 
CYP1A1 and CYP1B11A [9–12]. The formed 6-hydroxymelatonin is then conjugated with sulphate or 
glucuronide to be excreted in the urine. Another important metabolite is N-acetylserotonin which is 
formed by O-demethylation, and may represent as much as 20% of a melatonin administered dose [13].  
Melatonin is also metabolized in tissues by oxidative pyrrole ring cleavage into kynuramine 
derivatives. The primary cleavage product is N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), 
which is deformylated, either by arylamine formamidase or by hemoperoxidase, to N1-acetyl-5-
methoxykynuramine (AMK) [14]. It has been proposed that AFMK is the primary active metabolite of 
melatonin to mediate cytoprotection [15]. Melatonin is also converted into cyclic 3-hydroxymelatonin 
in a process that directly scavenges two hydroxyl radicals [15]. Due to its rapid metabolism, melatonin 
has a short half-life of approximately one hour, although there is a marked inter-individual variation in 
plasma levels of melatonin after oral administration [16–18]. 
The two membrane melatonin receptors cloned so far (MT1 and MT2) have seven membrane 
domains and belong to the superfamily of G-protein coupled receptors [19]. MT1 and MT2 receptors 
are found in the cell membrane as dimers and heterodimers. GPR50, a G-protein coupled melatonin 
receptor ortholog that does not bind melatonin itself, dimerizes with MT1 receptors and can block 
melatonin binding [20]. The human MT2 receptor exhibits a lower affinity than the human MT1 
receptor and becomes desensitized after exposure to melatonin, presumably by internalization. 
As representatives of the G-protein coupled receptor family, MT1 and MT2 receptors act through a 
number of signal transduction mechanisms [19]. The MT1 receptor is coupled to G proteins that 
mediate adenylyl cyclase inhibition and phospholipase C activation. The MT2 receptor is also coupled 
to the inhibition of adenylyl cyclase, and it additionally inhibits the soluble guanylyl cyclase pathway. 
By using receptor autoradiography with the nonselective 2-[125I]iodomelatonin ligand and real-time 
quantitative reverse transcription–polymerase chain reaction to label melatonin receptor mRNA, MT1 
and MT2 receptors has been identified brain regions. At the level of the hippocampus, MT2 receptors 
were detected in CA3 and CA4 pyramidal neurons, which receive glutamatergic excitatory inputs from 
the entorhinal cortex, whereas MT1 receptors were predominantly expressed in CA1 [6]. 
Melatonin also binds to transcription factors belonging to the retinoic acid receptor superfamily, in 
particular, splice variants of RORα (RORα1, RORα2, and RORα isoform d) and RZRβ [21,22]. 
Retinoic acid receptor subforms are ubiquitously expressed in mammalian tissues [22]. 
Melatonin is a powerful antioxidant that scavenges ·OH radicals as well as other radical oxygen 
species (ROS) and radical nitrogen species (RNS), and that gives rise to the cascade of metabolites 
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mentioned above that share antioxidant properties [23]. Melatonin also acts indirectly to promote gene 
expression of antioxidant enzymes and to inhibit gene expression of prooxidant enzymes [24–27].  
In particular, this holds for glutathione peroxidase (GPx) and for glutathione reductase (GRd), 
presumably in response to GPx-dependent increases in GSSG, the oxidized form of glutathione (GSH). 
Melatonin contributes to maintain normal brain GSH levels [28] by stimulating GSH biosynthesis via 
γ-glutamylcysteine synthase and glucose-6-phosphate dehydrogenase [26,29]. Melatonin has a 
demonstrated superiority to vitamin C and E in protection against oxidative damage and in scavenging 
free radicals [23]. 
Melatonin has significant anti-inflammatory properties presumably by inhibiting nuclear factor κB 
(NFκB) binding to DNA, thus, decreasing the synthesis of proinflammatory cytokines through 
inhibition of cyclooxygenase (Cox) [30], mainly Cox-2 [31], and by suppression of inducible nitric 
oxide (NO) synthase (iNOS) gene expression [32]. Melatonin was shown to protect from oxidative 
stress at physiological concentrations [23,33]. Although melatonin’s direct action as an antioxidant 
agent is mostly independent of receptor interaction [34], the upregulation of antioxidant enzymes by 
the methoxyindole involves nuclear transcription and in some cases RZR/RORα receptors [35]. 
The efficacy of melatonin in inhibiting oxidative damage has been tested in a variety of neurological 
disease models. In addition to the animals models of AD discussed below, melatonin has been shown to 
lower neural damage due to cadmium toxicity [36,37], hyperbaric hyperoxia [38,39], δ-aminolevulinic 
acid toxicity [40–42], γ radiation [43–45], focal ischemia [46,47], brain trauma [48–50], and a number of 
neurotoxins [51]. 
Melatonin’s neuroprotective properties, as well as its regulatory effects on circadian disturbances, 
validate its benefits as a therapeutic substance in the preventive treatment of AD. Moreover, melatonin 
exerts anti-excitatory, and at sufficient dosages, sedating effects [52,53], thus that a second 
neuroprotective mode of action may exist involving the γ-aminobutyric acid (GABA)-ergic system as a 
mediator. This view is supported by studies indicating that melatonin protects neurons from the 
toxicity of the amyloid-β (Aβ) peptide (a main neurotoxin involved in AD) via activation of GABA 
receptors [54]. 
Early studies on the anti-excitotoxic actions of melatonin employed kainate, an agonist of 
ionotropic glutamate receptors, and gave support to the hypothesis that melatonin prevents neuronal 
death induced by excitatory amino acids [55,56]. It has also been reported that administration of 
melatonin reduces the injury of hippocampal CA1 neurons caused by transient forebrain  
ischemia [57,58] or high glucocorticoid doses [59]. 
The various types of toxicities listed above can result in neuronal death by necrosis or apoptosis. 
Apoptotic neuronal death requires RNA and protein synthesis and depletion of trophic factors. 
Apoptosis also involves single-strand breaks of DNA and neurotrophic factors have been found to 
rescue neurons from this type of death [60]. They may act via cellular anti-apoptotic components, such 
as the B cell lymphoma proto-oncogene protein (Bcl-2). In vitro studies indicate that melatonin 
enhances expression of Bcl-2 and prevents apoptosis [61–63]. In addition, melatonin directly inhibits 
the opening of the mtPTP, thereby rescuing cells [64–66]. 
The aging process of the brain is presently known in sufficient detail [67]. A number of senescence 
processes rely on mitochondrial damage including apoptosis via cardiolipin peroxidation,  
cytochrome C release and mtPTP breakdown and reduction of the mitochondrial mass. The blockade 
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of the electron transport chain leads to insufficient energy supply and impaired cell function and 
viability. The augmented ROS and RNS generation cause concomitant damage to endothelia, DNA 
proteins, and lipids. In addition neuronal overexcitation with calcium overload and activation of 
microglia occur with age. As a consequence of DNA damage, an increased telomere attrition takes 
place together with a reduction in cells with high proliferative capacity like immune progenitor cells 
thus leading to immunosenescence [67]. This situation is accompanied by the augmentation of autoimmune 
responses and by an inflammatory process leading to the increase of proinflammatory cytokines. 
Evidence derived from animal studies indicates that melatonin may curtail most aspects of brain 
aging [67]. First, via action on central and peripheral circadian oscillators melatonin increases the 
depressed rhythm amplitudes and poor coordination of rhythms seen in the aged individuals. 
Melatonin affects clock protein expression and may modulate the disrupted metabolic sensing in 
senescence. Through the support of mitochondrial electron flux and reduction of electron overflow 
melatonin improves respiratory efficiency and energy supply and prevents apoptosis. The reduction of 
ROS and RNS exerted via radical scavenging, upregulation of antioxidant enzymes, inhibition of 
prooxidant enzymes, increase of GSH, and lower radical formation brings about a reduced damage to 
proteins, lipids, and DNA, together with inhibition of oxidant-induced telomere attrition and neuronal 
overexcitation. The antiinflammatory actions of melatonin are crucial in reducing aging-related 
processes, as well as the improved insulin sensitivity and counteraction of the metabolic syndrome 
attributed to the methoxyindole. Lastly, melatonin modulates natural and adaptive immunity and 
improves immunosenescence, in part via a greater number of cells with high proliferative capacity, 
including leukocytes, stem, and progenitor cells [67]. 
3. Overview of Melatonin Therapy for Alzheimer’s Disease—Theory and Mode of Action 
Extracellular senile plaques, formed mainly by Aβ deposits, and intracellular neurofibrillary 
tangles, resulting mainly from abnormally hyperphosphorylated microtubule-associated protein (MAP) 
tau are the major pathological characteristic of AD. Aβ plays an important role in promoting neuronal 
degeneration in AD turning neurons vulnerable to age-related increases in the levels of oxidative stress 
and an altered cellular energy metabolism. 
Aβ is composed by 39–43 amino acid residues derived from its precursor, the amyloid precursor 
protein (APP) [68]. APP is proteolytically processed by α- or β-secretases in different pathways. The 
α-non-amyloidogenic pathway involves cleavage of APP by α-secretase to release an N-terminal 
fragment of APP, which after cleavage by γ-secretase precludes the formation of the Aβ [68]. The  
β-amyloidogenic pathway includes β-secretase, which results in the formation of intact Aβ peptide and 
is mediated by the sequential cleavage of β-secretase and γ-secretase at the N- and C-terminal of  
Aβ sequence [68]. 
Melatonin inhibited the normal levels of soluble APP secretion in different cell lines interfering 
with APP maturation [69]. Additionally, the administration of melatonin efficiently reduces Aβ 
generation and deposition in vivo [70,71] and in vitro [69,72–74]. Generally, the results in transgenic 
mice support the view that melatonin should be given at an early phase to regulates APP and Aβ 
metabolism mainly by preventing their formation, with little anti-amyloid effect later on. Thus, 
melatonin therapy in old Tg2576 mice starting at 14 months of age could not prevent additional Aβ 
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deposition [75] while a similar treatment starting at the fourth month of age was effective to reduce  
it [70]. As amyloid plaque pathology typically is seen in 10- to 12-month-old Tg2576 mice [76] the 
data point out to the effectiveness of melatonin in preventing early amyloid plaque formation rather 
than afterwards. 
How melatonin exerts its inhibitory effect on the generation of Aβ remains undefined. The 
proteolytic cleavage of APP by α-secretase pathway is regulated by many physiological and 
pathological stimuli particularly through protein kinase (PK) C activation and secretase-mediated 
cleavage of APP. The inhibition of glycogen synthase kinase-3 (GSK-3) and upregulation of c-Jun  
N-terminal kinase result in high activity of matrix metalloproteinases with increasing degradation of 
Aβ [77]. The activity of insulin-degrading enzyme (IDE) that regulates the levels of insulin, Aβ and 
APP, decreased after Aβ increase [78]. GSK-3 interacts with presenilin-1, a cofactor of γ-secretase, the 
phosphorylation of GSK-3 by PKC leading to γ-secretase inactivation. Indeed, GSK-3 can be one of 
the common signaling pathways, increasing Aβ generation and tau hyperphosphorylation, and 
melatonin could regulate APP processing through PKC and GSK-3 pathways (Figure 1). 
Melatonin interacts with Aβ40 and Aβ42 and inhibits progressive β-sheet and/or amyloid fibrils [79,80]. 
This interaction between melatonin and Aβ appears to depend on structural melatonin characteristics 
rather than on its antioxidant properties, as it could not be mimicked by other free radical  
scavengers [79]. By blocking the formation of secondary sheets, melatonin not only reduces 
neurotoxicity but also facilitates peptide clearance increasing proteolytic degradation, e.g., by IDE. 
Figure 1. Effect of melatonin on impaired brain insulin signaling in AD. The figure 
schematizes the processes linking impaired insulin/insulin receptor with senile plaques and 
neurofibrillary tangles. In parentheses, the demonstrated action of melatonin as discussed 
in the text. 
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Oxidative stress plays a central role in Aβ-induced neurotoxicity and cell death. Accumulating data 
support that melatonin effectively protects cells against Aβ-induced oxidative damage and cell death  
in vitro [81,82] and in vivo [70,81,83–85]. In cells and animals treated with Aβ, melatonin could exert 
its protective activity through an antioxidant effect, whereas in APP transfected cells and transgenic 
animal models, the underlying mechanism may involve primarily the inhibition of generation of  
β-sheets and/or amyloid fibrils. Aggregated Aβ generates ROS that produce neuronal death through 
damage of neuronal membrane lipids, proteins and nucleic acids. Protection from Aβ toxicity by 
melatonin was observed, especially at the mitochondrial level [86,87]. 
The hyperphosphorylation of tau reduces tau capacity to prevent microtubule changes and the 
disruption of the cytoskeleton ensues [88,89]. The extent of neurofibrillary pathology correlates with 
the severity of dementia in AD patients. The level of hyperphosphorylated tau is three to four times 
higher in the brain of AD patients than in normal adult brains [90,91]. 
Melatonin efficiently attenuates tau hyperphosphorylation by affecting protein kinases and 
phosphatases in a number of experimental models including exposure of N2a and SH-SY5Y 
neuroblastoma cells to wortmannin [92], calyculin A [93–95], and okadaic acid [96–99]. Melatonin 
also antagonizes the oxidative stress given by these agents [100,101]. The inhibition of melatonin 
biosynthesis in rats not only resulted in impairment of spatial memory, but also induced an increase in 
tau phosphorylation, an effect prevented by melatonin supplementation [102]. 
Oxidative stress is known to influence tau phosphorylation state [103,104]. The accumulation of 
misfolded and aggregated proteins in brain neurons of AD is considered a consequence of oxidative 
stress, in addition to the molecular structural changes due to age [105]. As melatonin prevents, as an 
antioxidant and free radical scavenger, overproduction of free radicals, it seems feasible that the 
prevention of tau phosphorylation by melatonin is partly occurring due to its antioxidant activity.  
In addition several studies indicated melatonin may act as a modulator of enzymes in a way that is 
unrelated to its antioxidant properties. These include the regulation by melatonin of PKA [100,101], 
PKC [106,107], Ca2+/calmodulin-dependent kinase II [108–110] and mitogen-activated protein  
kinase [111]. 
An important factor in the pathogenesis of AD is the activation of microglia resulting in a higher 
level of expression of proinflammatory cytokines [112–115]. Epidemiological studies have shown that 
the use of anti-inflammatory drugs decreases the incidence of AD [116]. Aβ-induced microglial 
activation is a major source of inflammatory response [117]. Melatonin attenuated the production of 
proinflammatory cytokines induced by Aβ, NFκB, and NO in the rat brain [85,118]. Moreover, the 
DNA binding activity of NFκB was inhibited by melatonin [119,120]. 
Another major event in the pathogenesis of AD is the deficit in cholinergic function [121]. Neurons 
in the nucleus basalis of Meynert, the main source of cholinergic innervation to the cerebral cortex and 
the hippocampus, undergo a profound and selective degeneration in AD brains [122]. The levels of 
acetylcholine (ACh) are reduced at the early stage of AD whereas the activities of the synthesizing and 
degrading enzymes choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) do not change 
until a late phase of AD [123,124]. As the decrease in ChAT activity in the neocortex of AD patients 
correlated with the severity of dementia, AChE inhibitors have become a standard treatment of mild to 
moderate AD [125]. 
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Melatonin has a protective effect on the cholinergic system. It prevents the peroxynitrite-induced 
inhibition of choline transport and ChAT activity in synaptosomes and synaptic vesicles [126]. 
Melatonin treatment of eight-month-old APP695 transgenic mice significantly improved the profound 
reduction in ChAT activity in the frontal cortex and the hippocampus [81]. Melatonin also antagonizes 
the spatial memory deficit and the decreased ChAT activity found in adult ovariectomized rats [127]. 
However, in rats perfused intracerebroventricularly with Aβ for 14 days, melatonin was unable to 
restore ChAT activity [128]. Melatonin inhibited lipopolysaccharide- and streptozotocin-induced 
increase in AChE activity [129]. Recently hybrids of the AChE inhibitor tacrine and melatonin were 
synthesized as new drug candidates for treating AD [130,131]. These hybrids showed better 
antioxidant and cholinergic-preserving activity than tacrine or melatonin alone. The direct intracerebral 
administration of one of these hybrids decreased induced cell death and Aβ load in the APP/PS1 
mouse brain parenchyma accompanied by a recovery of cognitive function [131]. 
There is a growing interest in the role of impaired brain insulin signaling in AD pathology.  
The disturbance of brain insulin/insulin-like growth factor 1 (IGF-1) signaling has been suggested  
to be a key causative event underlying AD, being linked to the presence of both senile plaques  
and neurofibrillary tangles [132–134]. This view, however, is not universally held [135]. An impaired 
insulin/insulin receptor (IR) signaling leads to decreased insulin-mediated activation of 
phosphoinositide 3-kinase (PI-3K)/Akt signaling activity, resulting in overactivation of GSK-3  
which directly promotes tau hyperphosphorylation and Aβ accumulation and senile plaques formation 
(Figure 1). The activity of IDE, that regulates the levels of insulin, Aβ and APP, decreased after Aβ 
deposition [78]. The administration of melatonin reportedly reduces the signs of metabolic  
syndrome, such as hyperglycemia, dyslipidemia, hyperinsulinemia, insulin resistance, weight gain, and 
hypertension [136,137]. Melatonin restores insulin/insulin receptor mechanisms and increases 
phosphoinositide 3-kinase/Akt signaling activity with a resultant inhibition of GSK-3 and less Aβ 
accumulation and tau hyperphosphorylation (see [6]). Additionally, disruption of insulin signaling 
leads to a decreased glucose transporter-1 (GLUT-1) and -3 (GLUT-3) expression, culminating in 
impaired cerebral glucose uptake/metabolism, another event counteracted by melatonin. The restored 
neuronal glucose metabolism augments tau N-acetylglucosamine acylation, thus reducing tau 
hyperphosphorylation (Figure 1). 
Figure 2 summarizes the major possible targets for medication in AD. The Food and Drug 
Administration (FDA) has only approved AChE inhibitors and N-methyl-D-aspartate (NMDA) 
receptor blockers for clinical use. As discussed above, melatonin has the unique property to affect all 
the physiopathological mechanisms depicted in Figure 2. Hence, its potential as a neuroprotector in 
AD deserves to be explored. 
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Figure 2. Possible targets for medication in AD. As discussed in the text, melatonin has the 
potential to affect all the mechanisms depicted in the figure. (*) Approved by the FDA. 
 
4. Clinical Aspects of Melatonin Application in AD 
In demented patients the severity of mental impairment correlated significantly with impaired 
nocturnal melatonin production [138]. This may be an early sign of the disease since cerebrospinal 
fluid (CSF) melatonin levels are reduced in AD patients autopsied at the preclinical stage Braak  
stage-1. Hence the reduction in CSF melatonin may be a marker for the early detection of AD [139]. 
Additionally plasma melatonin levels are lower in AD patients [140–143] and functionally impaired 
retinal-SCN-pineal connections were postulated as cause for this decrease [144]. Expression and 
activity of monoamine oxidase gene augmented, and β1-adrenoceptor mRNA levels decreased, in the 
pineal gland of AD patients [145]. In addition changes in melatonin receptor immunoreactivity 
occurred in the AD hippocampus [146,147]. Collectively the results indicate that replacement of 
melatonin levels can be a therapeutic strategy for arresting AD progression. 
“Sundowning”, a chronobiological phenomenon that includes disorganized thinking, reduced ability 
to maintain attention to external stimuli, wandering, agitation, and perceptual and emotional 
disturbances, is a situation commonly observed in AD patients. As a time-of-day related phenomenon, 
appearing in late afternoon or early evening [148,149], the possible therapeutic effect of melatonin was 
entertained. Table 1 summarizes the data indicating that melatonin, as a chronobiotic agent, may be 
effective in treating sundowning and irregular sleep-wake cycles in AD patients. 
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A review of the published results concerning melatonin use in AD [150] yielded eight reports  
(five open-label studies, two case reports) (N = 89 patients) supporting a possible efficacy of melatonin: 
sleep quality improved and in patients with AD sundowning was reduced and cognitive decay slowed 
progression. In six double blind, randomized placebo-controlled trials, a total number of 210 AD 
patients were examined. Sleep quality increased and sundowning decreased significantly and cognitive 
performance improved in four studies (N = 143) whereas there was absence of effects in two studies  
(N = 67) [150]. 
Another systematic search of studies published between 1985 and April 2009 on melatonin and 
sundowning in AD patients was published [151]. All papers on melatonin treatment in dementia were 
retrieved and the effects of melatonin on circadian rhythm disturbances were scored by means of 
scoring sundowning/agitated behavior, sleep quality, and daytime functioning. A total of 9 papers, 
including 4 randomized controlled trials (N = 243), and 5 case series (N = 87) were reviewed (Table 1). 
Two of the randomized controlled trials found a significant improvement in sundowning/agitated 
behavior. All five case series found an improvement [151]. Thus, whether melatonin has any value in 
treating AD remains uncertain. Probably, the heterogeneity of the group examined in fully developed 
AD makes it difficult to disclose any therapeutic effect in studies including a small number of  
patients [152]. Moreover, the reduced hippocampal expression of MT2 melatonin receptors in AD 
patients [146] and of MT1 receptors in the circadian apparatus may explain why melatonin treatment is 
erratic at this advanced stage of the disease [153,154]. 
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Table 1. Studies including treatment of Alzheimer’s disease (AD) patients with melatonin. 
Design Subjects Treatment Time Measured Results Reference 
Open-label study 10 AD patients 
3 mg melatonin p.o./daily at 
bed time 
3 weeks 
Daily logs of sleep and 
wake quality completed 
by caretakers 
7 out of 10 dementia patients having sleep 
disorders treated with melatonin showed a 
significant decrease in sundowning and reduced 
variability of sleep onset time 
[155] 
Open-label study 14 AD patients 
9 mg melatonin p.o./daily at 
bed time 
22 to 35 
months 
Daily logs of sleep and 
wake quality completed 
by caretakers.  
Neuro-psychological 
assessment 
Sundowning was no longer detectable in  
12 patients and persisted, although attenuated in 
2 patients. A significant improvement of sleep 
quality was found. Lack of progression of the 
cognitive and behavioral signs of the disease 
during the time they received melatonin 
[156] 
Case report 
Mono-zygotic twins 
with AD of 8 years 
duration 
One of the patients was treated 
with melatonin 9 mg p.o./daily 
at bed time. 
36 months 
Neuro-psychological 
assessment. 
Neuroimaging 
Sleep and cognitive function severely impaired 
in the twin not receiving melatonin as compared 
to the melatonin-treated twin 
[157] 
Open-label study 11 AD patients 
3 mg melatonin p.o./daily at 
bed time 
3 weeks 
Daily logs of sleep and 
wake quality 
Significant decrease in agitated behaviors in all 
three shifts; significant decrease  
in daytime sleepiness 
[158] 
Open-label,  
placebo-controlled trial 
14 AD patients 
6 mg melatonin p.o./daily at 
bed time or placebo 
4 weeks 
Daily logs of sleep and 
wake quality completed 
by caretakers. 
Actigraphy 
AD patients receiving melatonin showed a 
significantly reduced percentage of nighttime 
activity compared to a placebo group 
[159] 
Randomized double blind 
placebo-controlled  
cross over study 
25 AD patients 
6 mg of slow release melatonin 
p.o. or placebo at bed time 
7 weeks Actigraphy 
Melatonin had no effect on median total time 
asleep, number of awakenings or sleep efficiency
[160] 
Open-label study 45 AD patients 
6–9 mg melatonin p.o./daily at 
bed time 
4 months 
Daily logs of sleep and 
wake quality completed 
by caretakers.  
Neuro-psychological 
assessment 
Melatonin improved sleep and suppressed 
sundowning, an effect seen regardless of the 
concomitant medication employed 
[161] 
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Table 1. Cont. 
Randomized  
placebo-controlled  
clinical trial 
157 AD patients 
2.5-mg slow-release melatonin, 
or 10-mg melatonin or placebo 
at bed time 
2 months 
Actigraphy. Caregiver 
ratings of sleep quality
Non significant trends for increased nocturnal 
total sleep time and decreased wake after sleep 
onset in the melatonin groups. Caregiver ratings 
of sleep quality showed a significant 
improvement in the 2.5-mg sustained-release 
melatonin group relative to placebo 
[162] 
Double-blind,  
placebo-controlled study 
20 AD patients 
Placebo or 3 mg melatonin 
p.o./daily at bed time 
4 weeks 
Actigraphy.  
Neuro-psychological 
assessment 
Melatonin significantly prolonged the sleep time 
and decreased activity in the night. Cognitive 
function was improved by melatonin 
[163] 
Open-label study 7 AD patients 
3 mg melatonin p.o./daily at bed 
time 
3 weeks 
Actigraphy.  
Neuro-psychological 
assessment. 
Complete remission of day-night rhythm 
disturbances or sundowning was seen in  
4 patients, with partial remission in other 2 
[164] 
Randomized  
placebo-controlled study 
17 AD patients 
3 mg melatonin p.o./daily at bed 
time (7 patients). Placebo  
(10 patients) 
2 weeks 
Actigraphy.  
Neuro-psychological 
assessment. 
In melatonin-treated group, actigraphic nocturnal 
activity and agitation showed significant 
reductions compared to baseline 
[165] 
Case report 
68-year-old man with 
AD who developed 
rapid eye movement 
(REM) sleep behavior 
disorder 
5–10 mg melatonin p.o./daily at 
bed time. 
20 months Polysomno-graphy 
Melatonin was effective to suppress REM sleep 
behavior disorder 
[166] 
Randomized  
placebo-controlled study 
50 AD patients 
Morning light exposure  
(2500 lux, 1 h) and 5 mg 
melatonin (N = 16) or placebo 
(N = 17) in the evening 
10 weeks Actigraphy 
Light treatment alone did not improve nighttime 
sleep, daytime wake, or rest-activity rhythm. 
Light treatment plus melatonin increased 
daytime wake time and activity levels and 
strengthened the rest-activity rhythm 
[167] 
Randomized  
placebo-controlled study 
41 AD patients 
Melatonin (8.5 mg immediate 
release and 1.5 mg sustained 
release) (N = 24) or placebo  
(N = 17) administered at 22:00 h
10 days Actigraphy 
There were no significant effects of melatonin, 
compared with placebo, on sleep, circadian 
rhythms, or agitation 
[168] 
p.o.: per os. 
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Mild cognitive impairment (MCI) is the name given to signs and symptoms diagnosed in those who 
have an objective and measurable deficit in cognitive functions, but with a relative preservation of 
daily activities. Annual conversion rates to AD are as high as 10%–15% [169] and MCI represents a 
clinically important stage for identifying and treating individuals at risk. Indeed, the degenerative 
process in AD brain starts 20–30 years before the clinical onset of AD [170,171]. During  
this phase, the loads of plaques and tangles increase and at a certain threshold the first symptoms 
appear [172,173]. As mentioned above, CSF melatonin levels decrease in preclinical stages of AD, 
suggesting that the reduction of CSF melatonin may be an early trigger and marker for AD [139,145]. 
Although it is not known whether the relative melatonin deficiency is either a consequence or a cause 
of neurodegeneration, the loss in melatonin presumably aggravates the disease. 
We previously reported a retrospective analysis in which daily 3–9 mg of a fast-release melatonin 
preparation per os (p.o.) at bedtime for up to three years significantly improved cognitive and 
emotional performance and daily sleep/wake cycle in 25 MCI patients [174]. Recently we reported 
data from another series of 96 MCI outpatients, 61 of who had received daily 3–24 mg of a fast-release 
melatonin preparation p.o. at bedtime for 15 to 60 months in comparison to a similar group of 35 MCI 
patients who did not receive it [175]. In addition, all patients received the individual standard 
medication considered appropriate by the attending psychiatrist. 
Patients treated with melatonin exhibited significantly better performance in Mini–Mental State 
Examination and the cognitive subscale of the AD Assessment Scale. After application of a 
neuropsychological battery comprising a Mattis’ test, Digit-symbol test, Trail A and B tasks and the 
Rey’s verbal test, better performance was found in melatonin-treated patients for every parameter 
tested [175]. Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, 
concomitantly with the improvement in the quality of sleep and wakefulness [175]. These results 
further support that melatonin is a useful add-on drug for treating MCI in a clinical environment. 
Thus, an early initiation of melatonin treatment can be decisive for therapeutic success [75].  
In Table 2, published data concerning melatonin treatment in MCI are summarized. Six double blind, 
randomized placebo-controlled trials and two open-label retrospective studies (N = 782) consistently 
showed that the administration of daily evening melatonin improves sleep quality and cognitive 
performance in MCI patients. Therefore, melatonin treatment could be effective at early stages of the 
neurodegenerative disease. 
There are two reasons why it is beneficial to use melatonin in MCI patients. In the course of the 
neurodegenerative process, the age-related deterioration in circadian organization becomes significantly 
exacerbated and is responsible of behavioral problems like sundowning [176]. Age-related cognitive 
decline in healthy older adults can be predicted by the fragmentation of the circadian rhythm in 
locomotor behavior. Hence, replacement of the low melatonin levels occurring in brain [139,145] can 
be highly beneficial in MCI patients.  
On the other hand, the bulk of information on the neuroprotective properties of melatonin derived 
from experimental studies (see for [177,178]) makes it highly desirable to employ pharmacological 
doses in MCI patients with the aim of arresting or slowing disease progression. Although the pineal 
gland secretes melatonin that circulates in the blood and the CSF [179], recent data support the 
hypothesis that, in sheep, and presumably in humans, only CSF melatonin, and not bloodstream 
melatonin, can provide most of melatonin to the cerebral tissue in high concentrations [180]. 
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Significant concentration gradients oriented from the ventricle (close to the CSF) to the cerebral tissue, 
with concentrations varying by a factor of 1 to 125 were demonstrated. Hence, besides supporting the 
role of CSF in physiological availability of melatonin [179] these results imply that high, 
pharmacological amounts of melatonin must be given to have access to the brain. 
The mechanisms accounting for the therapeutic effect of melatonin in MCI patients remain to be 
defined. Melatonin treatment mainly promotes slow wave sleep in the elderly [181] and can be 
beneficial in MCI by augmenting the restorative phases of sleep, including the augmented secretion of 
GH and neurotrophins. 
As outlined above, melatonin acts at different levels relevant to the development and manifestation 
of AD. The antioxidant, mitochondrial, and antiamyloidogenic effects can possibly interfere with the 
onset of the disease. Therefore, the time when melatonin treatment begins can be decisive for the final 
response [75]. 
One important aspect to be considered is the melatonin dose employed, which may be unnecessarily 
low when one takes into consideration the binding affinities, half-life, and relative potencies of the 
different melatonin agonists on the market. In addition to being generally more potent than the native 
molecule, melatonin analogs are employed in considerably higher amounts [182]. Licensed doses of 
the melatonin receptor agonist ramelteon vary from 8 to 32 mg/day while agomelatine has been 
licensed for treatment of major depressive disorder at doses of 25–50 mg/day. In clinical studies 
involving healthy human subjects, tasimelteon (Vanda Pharmaceuticals, Washington, DC, USA), 
another melatonin receptor agonist recently approved by the FDA is administered at doses of 20 to  
100 mg/day [183] while pharmacokinetics, pharmacodynamics and safety of the melatonin receptor 
agonist TIK-301 (Tikvah Pharmaceuticals, Atlanta, GA, USA) have been examined in a placebo 
controlled study using 20 to 100 mg/day [184]. Therefore, studies of MCI with melatonin doses in the 
range of 100–300 mg/day are further warranted. 
A combination therapy of melatonin with a melatonin receptor agonist could theoretically be 
beneficial for AD patients, especially if the melatonin receptor agonist has a better pharmacokinetic 
profile than melatonin. However, melatonin receptor agonists have shown limited benefit in murine 
models of AD [185]. 
As melatonin is cleared very rapidly from the bloodstream strategies such as inhibition of melatonin 
degradation and clearance from the body could be a useful add-on to exogenous melatonin treatment. 
Indeed, pharmacological plasma levels of melatonin could be affected as a result of concurrent 
exposure to chemicals that modulate the expression of CYP1A2. For example, fluvoxamine, a potent 
inhibitor of CYP1A2 and to a lesser extent of CYP2C19, augmented plasma melatonin  
levels [186,187]. Likewise, the concomitant consumption of caffeine whose metabolism is principally 
catalyzed by CYP1A2, more than doubled plasma levels and increased the bioavailability of  
melatonin [188]. Another candidate is 5-methoxypsoralen, a drug used for the treatment of psoriasis, 
which elevates plasma levels of endogenous and exogenous melatonin [189–191]. 
It should be stressed that melatonin has a high safety profile, it is usually remarkably well tolerated 
and, in some studies, it has been administered to patients at very large doses [16,192–195]. Melatonin 
(300 mg/day) for up to three years decreased oxidative stress in patients with amyotrophic lateral 
sclerosis [192].  
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In children with muscular dystrophy, 70 mg/day of melatonin reduced cytokines and lipid  
peroxidation [193]. Doses of 80 mg melatonin hourly for 4 h were given to healthy men with no 
undesirable effects other than drowsiness [16]. In healthy women, given 300 mg melatonin/day for 
four months, there were no side effects [194]. A recent randomized controlled double-blind clinical 
trial on 50 patients referred for liver surgery indicated that a single preoperative enteral dose of  
50 mg/kg melatonin (i.e., an equivalent to 3 g for a 60-kg adult) was safe and well tolerated [195]. 
Another outcome of the study recently reported [175] was that when melatonin is employed much 
less benzodiazepines are needed to treat sleep disturbances in MCI. Since, as above-mentioned, 
melatonin and benzodiazepines shared some neurochemical (i.e., interaction with GABA-mediated 
mechanisms in brain [196]) and behavioral properties (e.g., a similar day-dependent anxiolytic  
activity [46]) melatonin therapy was postulated to be an effective tool to decrease the dose of 
benzodiazepines needed in patients [155,197–199]. A recent retrospective analysis of a German 
prescriptions database identified 512 patients who had initiated treatment with prolonged release 
melatonin (2 mg) over a 10-month period [200]. From 112 patients in this group who had previously 
used benzodiazepines, 31% discontinued treatment with benzodiazepines three months after beginning 
prolonged release melatonin treatment. The discontinuation rate was higher in patients receiving two 
or three melatonin prescription [200]. The prolonged use of benzodiazepines and benzodiazepine 
receptor agonists (Z-drugs) is related to severe withdrawal symptoms and potential dependency, which 
has become a public health issue leading to multiple campaigns to decrease consumption of these 
drugs. A recent pharmacoepidemiological study concluded that these campaigns generally failed when 
they were not associated with the availability and market of melatonin [201] 
5. Conclusions 
In conclusion, the question as to whether melatonin has a therapeutic value in preventing or treating 
MCI, affecting disease initiation or progression of the neuropathology and the mechanisms involved, 
deserves to be further analyzed. Double-blind multicenter studies are needed to explore and investigate 
the potential and usefulness of melatonin as an antidementia drug at the early stage of disease. 
As melatonin exhibits both hypnotic and chronobiotic properties, it has been therapeutically used 
for treatment of age-related insomnia as well as of other primary and secondary insomnia [202,203].  
A consensus of the British Association for Psychopharmacology on evidence-based treatment of 
insomnia, parasomnia, and circadian rhythm sleep disorders concluded that melatonin at a dose of  
2 mg is the first choice treatment when a hypnotic is indicated in patients over 55 years [204]. 
As shown by the binding affinities, half-life and relative potencies of the different melatonin 
agonists in the market it is clear that studies using these low doses of melatonin are unsuitable to give 
appropriate comparison with the effect of the above mentioned compounds, which in addition to being 
generally more potent than the native molecule are employed in considerably higher amounts [205]. 
Therefore, further studies employing higher melatonin doses are needed to clarify its potential 
therapeutical neuroprotective implications in humans. From animal studies it is clear that a number of 
preventive effects of melatonin, such as those in neurodegenerative disorders, need high doses of 
melatonin to become apparent [177]. If one expects melatonin to be an effective neuroprotector it is 
likely that the low doses of melatonin employed thus far are not very beneficial. 
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Table 2. Studies including treatment of mild cognitive impairment (MCI) patients with melatonin. 
Design Subjects Treatment Time Measured Results Reference 
Double-blind,  
placebo-controlled, 
crossover study 
10 patients 
with MCI 
6 mg melatonin p.o./daily at 
bed time 
10 days 
Actigraphy. Neuro-psychological 
assessment 
Melatonin enhanced the rest-activity rhythm and 
improved sleep quality. The ability to remember 
previously learned items improved along with a 
significant reduction in depressed mood 
[206] 
Double-blind,  
placebo-controlled  
pilot study 
26 patients 
with  
age-related 
MCI 
1 mg melatonin p.o. or 
placebo at bed time 
4 weeks 
Sleep questionnaire and cognitive 
tests at baseline and at 4 weeks 
Melatonin administration improved reported 
morning “restedness” and sleep latency after 
nocturnal awakening. It also improved scores on 
the California Verbal Learning  
Test-interference subtest. 
[207] 
Randomizeddouble blind, 
placebo-controlled study 
354 patients 
with  
age-related 
MCI 
Prolonged release melatonin 
(Circadin, 2 mg) or placebo, 
2 h before bedtime 
3 weeks 
Leeds Sleep Evaluation and 
Pittsburgh Sleep 
QuestionnairesClinical Global 
Improvement scale score and 
quality of life. 
Melatonin resulted in significant and clinically 
meaningful improvements in sleep quality, 
morning alertness, sleep onset latency and quality 
of life 
[208] 
Open-label,  
retrospective study 
60 MCI  
out-patients 
35 patients received daily  
3–9 mg of a fast-release 
melatonin preparation p.o. at 
bedtime. Melatonin was 
given in addition to the 
standard medication 
9–24 months 
Daily logs of sleep and wake 
quality. Initial and final  
neuro-psychological assessment. 
Abnormally high Beck Depression Inventory 
scores decreased in melatonin-treated patients, 
concomitantly with an improvement in 
wakefulness and sleep quality. Patients treated 
with melatonin showed significantly better 
performance in neuropsychological assessment. 
[174] 
Long-term, double-blind, 
placebo-controlled, 2 × 2 
factorial randomized study
189 patients 
with  
age-related 
cognitive 
decay 
Long-term daily treatment 
with whole-day bright  
(1000 lux) or dim (300 lux) 
light. Evening melatonin 
(2.5 mg) or placebo 
1 to 3.5 years
Standardized scales for cognitive 
and noncognitive symptoms, 
limitations of activities of daily 
living, and adverse effects assessed 
every 6 months. 
Light attenuated cognitive deterioration and 
ameliorated depressive symptoms. Melatonin 
shortened sleep onset latency and increased sleep 
duration but adversely affected scores for 
depression. The combined treatment of bright 
light plus melatonin showed the best effects. 
[209] 
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Table 2. Cont. 
Prospective, randomized, 
double-blind,  
placebo-controlled, study 
22 patients 
with  
age-related 
cognitive 
decay 
Patients received 2 months of 
melatonin (5 mg p.o./day) 
and 2 months of placebo 
2 months 
Sleep disorders were evaluated 
with the Northside Hospital Sleep 
Medicine Institute test. Behavioral 
disorders were evaluated with the 
Yesavage Geriatric Depression 
Scale and Goldberg Anxiety Scale.
Melatonin treatment significantly improved sleep 
quality scores. Depression also improved 
significantly after melatonin administration. 
[210] 
Randomizeddouble-blind, 
placebo-controlled study 
25 MCI  
out-patients 
11 patients received an oily 
emulsion of  
docosa-hexaenoic  
acid-phospho-lipids 
containing melatonin (10 mg) 
and tryptophan (190 mg) 
12 weeks 
Neuro-psychological assessment of 
orientation and cognitive functions, 
short-term and long-term memory, 
attentional abilities, executive 
functions, visuo-constructional and 
visuo-spatial abilities, language  
and mood. 
Older adults with MCI had significant 
improvements in several measures of cognitive 
function when supplemented with the oily 
emulsion containing melatonin and tryptophan 
for 12 weeks, compared with the placebo. The 
antioxidant capacity of erythrocytes and 
membrane lipid composition improved  
after treatment. 
[211,212] 
Open-label,  
retrospective study 
96 MCI  
out-patients 
61 patients received daily  
3–24 mg of a fast-release 
melatonin preparation p.o. at 
bedtime. Melatonin was 
given in addition to the 
standard medication 
15–60 months
Daily logs of sleep and wake 
quality. Initial and final  
neuro-psychological assessment. 
Abnormally high Beck Depression Inventory 
scores decreased in melatonin-treated patients, 
concomitantly with an improvement in 
wakefulness and sleep quality. Patients treated 
with melatonin showed significantly better 
performance in neuropsychological assessment. 
Only 6 out of 61 patients treated with melatonin 
needed concomitant benzodiazepine treatment vs. 
22 out of 35 MCI patients not  
receiving melatonin. 
[175] 
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